title: Personalized therapy of sarcomas: integration of biomarkers for improved diagnosis, prognosis, and therapy selection.
abstract: An improved understanding of cancer's molecular diversity at the genetic, proteomic, and epigenetic levels has made it evident that "sarcoma" comprises more than 50 different types, each as unique as, for example, breast carcinoma is from colon carcinoma. Sarcomas exhibit characteristic differences in cell of origin, disease site, likelihood and site of metastasis, growth propensity, and chemosensitivity. Additionally, as many as one third of sarcomas harbor specific chromosomal translocations that can be used to discriminate one subtype from another. Although biomarkers can be integrated into clinical practice to improve diagnostic accuracy and predict treatment response, a number of challenges hinder their widespread use. This review addresses the current use of biomarkers for clinical oncology, with special emphasis on diagnosis, staging, and grading. It also discusses types of biomarkers that are emerging to aid selection of therapy for patients with sarcoma. Finally, we consider practical factors that appear to limit biomarker integration into clinical practice.
authors.affiliation: Laboratory of Sarcoma Molecular Therapeutics, Department of Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 450, 1515 Holcombe Boulevard, Houston, TX 77030, USA. jaludwig@mdanderson.org
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Ludwig
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D011379:Prognosis; D012509:Sarcoma / Q000737:chemistry / Q000175:diagnosis / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000737:chemistry / Q000175:diagnosis / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor
references.citation: J Clin Oncol. 1996 Apr;14(4):1245-51
references.pmid: 8648380
references.citation: Ann N Y Acad Sci. 2003 Mar;983:142-50
references.pmid: 12724219
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8828-34
references.pmid: 16314643
references.citation: J Clin Oncol. 1993 Mar;11(3):449-53
references.pmid: 8445419
references.citation: Cancer Res. 1999 Apr 1;59(7):1428-32
references.pmid: 10197607
references.citation: Cancer. 2005 May 1;103(9):1881-90
references.pmid: 15772959
references.citation: Mol Med. 2000 Jan;6(1):50-9
references.pmid: 10803408
references.citation: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references.pmid: 17237035
references.citation: J Clin Oncol. 2007 Nov 1;25(31):4909-13
references.pmid: 17971587
references.citation: Cancer. 2001 Aug 15;92(4):869-74
references.pmid: 11550160
references.citation: J Pathol. 2006 Apr;208(5):624-32
references.pmid: 16463269
references.citation: Jpn J Clin Oncol. 2007 Dec;37(12):955-60
references.pmid: 18211986
references.citation: Cancer. 2005 Jan 15;103(2):402-8
references.pmid: 15578681
references.citation: Semin Oncol. 2002 Jun;29(3):294-300
references.pmid: 12063683
references.citation: Mol Cancer Res. 2007 Oct;5(10):991-9
references.pmid: 17951400
references.citation: J Clin Oncol. 2008 Feb 10;26(5):729-35
references.pmid: 18258980
references.citation: J Clin Oncol. 1998 Apr;16(4):1248-55
references.pmid: 9552022
references.citation: Urol Oncol. 2000 Sep 1;5(5):214-216
references.pmid: 10973710
references.citation: Oncology. 2005;69(4):326-32
references.pmid: 16293972
references.citation: J Clin Oncol. 2002 Feb 1;20(3):776-90
references.pmid: 11821461
references.citation: Int J Cancer. 2001 May 20;95(3):168-75
references.pmid: 11307150
references.citation: Cell Mol Biol Lett. 2007;12(4):556-72
references.pmid: 17588222
references.citation: J Clin Oncol. 2002 Feb 1;20(3):791-6
references.pmid: 11821462
references.citation: J Clin Oncol. 2007 May 1;25(13):1760-4
references.pmid: 17470866
references.citation: Nat Genet. 2003 Mar;33 Suppl:238-44
references.pmid: 12610533
references.citation: J Clin Oncol. 2001 Feb 15;19(4):980-91
references.pmid: 11181660
references.citation: Cancer. 2004 Nov 15;101(10):2270-5
references.pmid: 15484214
references.citation: Wien Klin Wochenschr. 2004 Feb 28;116(4):135-9
references.pmid: 15038405
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9369-76
references.pmid: 16361637
references.citation: Future Oncol. 2007 Aug;3(4):381-92
references.pmid: 17661712
references.citation: Oncol Rep. 2003 Jan-Feb;10(1):181-4
references.pmid: 12469167
references.citation: N Engl J Med. 2001 Apr 5;344(14):1038-42
references.pmid: 11287973
references.citation: Clin Exp Metastasis. 2008;25(4):427-35
references.pmid: 18301993
references.citation: Clin Orthop Relat Res. 2007 Jun;459:229-36
references.pmid: 17353802
references.citation: Nat Biotechnol. 2003 Jul;21(7):742-3
references.pmid: 12833089
references.citation: J Orthop Res. 2007 Jan;25(1):116-21
references.pmid: 17034065
references.citation: Cancer Res. 2000 Sep 15;60(18):5134-42
references.pmid: 11016640
references.citation: J Clin Oncol. 1992 Jan;10(1):5-15
references.pmid: 1370176
references.citation: Semin Oncol. 2002 Jun;29(3):213-21
references.pmid: 12063674
references.citation: J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61
references.pmid: 11459866
references.citation: J Clin Oncol. 2007 Jul 1;25(19):2755-63
references.pmid: 17602081
references.citation: Nat Rev Cancer. 2005 Nov;5(11):845-56
references.pmid: 16239904
references.citation: Oncogene. 2007 Nov 1;26(50):7170-4
references.pmid: 17525744
references.citation: Semin Surg Oncol. 2003;21(1):3-7
references.pmid: 12923909
references.citation: Cancer. 2006 Apr 1;106(7):1617-23
references.pmid: 16518826
references.citation: Oncologist. 2002;7(4):348-59
references.pmid: 12185297
references.citation: Pediatr Radiol. 2004 Aug;34(8):595-605
references.pmid: 15103428
references.citation: Cancer. 2007 Sep 15;110(6):1351-60
references.pmid: 17661343
references.citation: J Clin Oncol. 1997 Feb;15(2):583-8
references.pmid: 9053480